

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : A61K 9/52, B01J 13/02 A61L 15/03	A1	(11) International Publication Number: WO 89/11850 (43) International Publication Date: 14 December 1989 (14.12.89)
(21) International Application Number: PCT/US89/02454 (22) International Filing Date: 8 June 1989 (08.06.89) (30) Priority data: 204,214 8 June 1988 (08.06.88) US (60) Parent Application or Grant (63) Related by Continuation US 204,214 (CIP) Filed on 8 June 1988 (08.06.88) (71)(72) Applicant and Inventor: FOUNTAIN, Michael, W. [US/US]; 12100 Valley Trail, Knoxville, TN 37922 (US). (74) Agents: BRADLEY, James, P. et al.; Richards, Harris, Medlock & Andrews, 1201 Elm Street, Suite 4500, Dal- las, TX 75270-2197 (US).		(81) Designated States: AT (European patent), AU, BE (Euro- pean patent), BR, CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), US. Published <i>With international search report.</i>
(54) Title: METHOD FOR MAKING SOLVENT DILUTION MICROCARRIERS (57) Abstract A method for forming vehicles for encapsulating passenger molecules which have been named solvent dilution microcarri- ers (SDMC's), and the products of this method are disclosed. The process allows for immediate or delayed formation of the SDMC's following the formation of a shelf stable solution by the dissolution of amphoteric bilayer-forming materials, a solvent, the passenger molecule, addition of aqueous solution, and further addition of solvent. The SDMC's are formed from the shelf stable solution by dilution into an aqueous system, aerosolization, or evaporation and rehydration <i>in situ</i> . Also disclosed are methods of using the SDMC's for treating wounds.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IT	Italy	RO	Romania
BJ	Benin	JP	Japan	SD	Sudan
BR	Brazil	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LJ	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

METHOD FOR MAKING SOLVENT DILUTION MICROCARRIERS

TECHNICAL FIELD

5 This invention relates to the art of enclosing
passenger molecules in a amphipathic carrier structure.

BACKGROUND OF THE INVENTION

There have been numerous attempts in the prior art to develop lipid-based vesicles which are capable of entrapping various materials of interest ("passenger molecules"). The known methods have generally resulted in generally spherical vesicles known as liposomes which are composed of a lipid bilayer having an inner space in which the entrapped material is held. These vesicles have been formed by methods employing mechanical agitation, for example, sonication or extrusion. After lipids in organic solvents were mixed, the resulting mixture was dried, followed by mechanical agitation and rehydration with the passenger molecule to be entrapped to encourage the lipid bilayer to enclose around the passenger molecule.

The liposomes formed by this method were generally heterogeneous in size and difficult to sterilize for in vivo applications. The stability or shelf-life of these liposomes was often very limited. The entrapment efficiency of passenger molecules was generally limited. The methods required, in general, toxic non-biocompatible solvents. The prior procedures were not applicable to aerosolization or formation of liposomes in situ. The vehicles formed by this method generally could be sterilized only by filtration as they exhibited heat lability. Moreover, prior methodology was not acceptably adaptable to the entrapment of certain passenger molecules.

SUMMARY OF THE INVENTION

It has now been found that an amphipathic vehicle (hereinafter referred to as "Solvent Dilution Micro-Carriers" or "SDMCs") can be made using a method which leads to entrapping the passenger molecule in the bilayer itself, or in association with a component of the bilayer, rather than inside the space created by a spherical bilayer. In this method, a solvent is mixed with an amphipathic material and a passenger molecule. A small amount of water is then added to form a turbid solution. Additional solvent is then added to form an optically clear solution, also referred to as the "formed solution." An organization step is performed either immediately or at a time remote from the previous steps. The organization may involve aerosolization, dilution into aqueous materials or drying and rehydrating. The amphipathic vehicles or solvent dilution microcarriers (SDMCs) are formed upon employment of the organization method. The vehicles formed by this method exhibit substantial size homogeneity and are capable of being sterilized by sterile filtration, heating or u.v. irradiation.

The process may be put on hold after the formed solution is made and that solution held until it is desired to perform the organization step.

The SDMCs formed by this new method are unique in that they entrap a wide range of passenger molecules. The SDMCs have a wide range of applications. Aerosols containing SDMCs may be advantageously applied to large surface areas, such as for example when the passenger molecule is a pesticide. On the other hand, aerosols are also applicable to delivery of medicaments and cosmetics such as antibiotics or hair sprays. The methodology of this invention is also useful for SDMC

formation in situ. The formed solution or SDMCs may be adsorbed on a surface such as bandage material and dried. Hydration allows the SDMC to deliver the passenger molecule to the desired site.

5 A sustained-release wound dressing material comprised of a foam bandage material and SDMCs has also been found.

DETAILED DESCRIPTION OF THE INVENTION

In the examples which follow, Solvent Dilution Microcarriers (SDMCs) were prepared by solubilizing at least one amphipathic material such as a surfactant (for example a biocompatible surfactant with good miscibility such as, but not limited to, Tween, Triton, sodium dodecyl sulfate (SDS), sodium laurel sulfate, and sodium octyl glucoside), a phospholipid, a mixture of phospholipids, polar lipids, sterols, sterol esters, neutral lipids, fatty acids, or other bilayer forming material into an appropriate solvent along with a passenger molecule (a material intended to solubilize in SDMCs). Various mixtures of amphipathic materials may be used. In some cases, it is convenient to select a commercial preparation of phospholipids. A preparation comprising about 75-97% mixed soy phosphatides may be used. For examples, commercial preparations of 75-80% mixed soy phosphatides, the remaining percentage being soy oils and preparations comprising 95-97% mixed soy phosphatides, the remaining percentage being soy oils are available. Commercial preparations having these characteristics are sold, for example, under the trade designations Alcolec S, Alcolec X-tra A and Alcolec LKE. The appropriate solvent is selected from those able to solubilize both the amphipathic material(s) and the passenger molecules. Generally, the most preferable solvent is a low molecular weight hydrocarbon such as ethanol, propanol, butanol, isopropanol, chloroform, acetone, methylene chloride or propyl glycol and the like. In addition, the solvent must be appropriate for the particular intended use of the SDMCs. If the SDMCs are to be employed in vivo such as for example in an intravenous admixture (i.v. admixture), the solvent must be utilizable without causing toxicity in that

application and generally must be biocompatible and readily miscible. In other applications, such as pesticide applications, the toxicity of the solvent is not as critical, but volatility becomes of more import. It is desirable in such case that the solvent volatilize immediately upon aerosolization. For formation in situ, such as for example when bandage material is impregnated for later rehydration, it is important that the solvent be non-flammable, that it volatilize quickly, and leave no residue in the matrix. Methylene chloride is one example of an appropriate solvent for such an application. Mixtures of solvents may be appropriate in some circumstances. The passenger molecule may be generally any material capable of being retained in a formed bilayer or associated with that bilayer. Passenger molecules such as antimicrobials, anti-inflammatories, anti-parasitics, dyes, radiolabels, radio-opaque compounds, fluorescent compounds, immunomodulating compounds, peptides, proteins, glycoproteins, lipoproteins, hormones, neurotransmitters, tumorocidal agents, growth factors, toxins, analgesics, anesthetics, mono and polysaccharides, narcotics, catalysts and enzymes are examples of the classes of substances which may be utilized. It is most preferred that the passenger molecule be lipophilic, however hydrophilic materials may also be utilized if they are capable of forming an association with the bilayer (i.e., the polar head group of the lipids). Cosmetics or cosmetic ingredients such as hair sprays, colorants, dyes, and the like are often highly appropriate for encapsulation in an SDMC. Medicaments used in mouthwashes, throat sprays, antiseptic sprays and the like also may be candidates for SDMC encapsulation. Drugs or tumorocidal agents for

i.v. admixture or other introduction method may be encapsulated in an SDMC utilizing the disclosed method. It is envisioned that SDMC vehicles containing toxic drugs may be effectively administered to a patient by coupling the SDMC to site-specific monoclonal antibodies, for example. In the alternative, the encapsulation alone may allow administration of certain drugs that could not be administered in unencapsulated form in an efficient or effective manner.

Following the mixing of the bilayer-forming material, passenger molecule, and solvent, water is added in the ratio of from about 4:1 (solvent to water) to about 10:1 (solvent to water), to form a turbid solution. Additional solvent is then added in the ratio from about 15:1 (solvent to water) to about 100:1 (solvent to water) or until the formed solution is optically clear. The additional solvent will generally be the same as used in the first step, but it may be a mixture of solvents or a different solvent which is appropriate to accomplish the desired result.

An organization step is done either immediately, or after storage of the formed solution for an indefinite period. The organization step may be aerosolization, dilution into an aqueous solution or drying and rehydrating. Aerosolization is performed simply by putting the material formed as described above into a sprayer or trigger pump such as would be commonly used for applying non-pressurized hair sprays, insecticides, and the like to other surfaces. Upon spraying the formed solution, it is mixed with air and the volatile solvent evaporates as the solution leaves the nozzle.

The dilution method of organization comprises diluting an aliquot of formed solution into water. Upon dilution, the SDMCs are formed. One preferred

appropriate dilution ratio is 1 to 10 (from 1 part formed solution to 9 parts water). The dilution ratio may range from about 1 to 5 to about 1 to 100.

5 The drying and rehydrating form of organization may be done by putting the formed solution onto a surface such as a bandage gauze, tampon, foam dressing, contraceptive sponge and the like and allowing the solvent to evaporate off very quickly. Upon hydrating the impregnated gauze, the SDMCs are formed in situ and
10 can perform their function of transporting the passenger molecule to the appropriate site on a wound, for example.

The SDMC vehicles formed by this method may be evaluated by utilizing a light scattering technique to
15 determine the presence of vesicles. This technique can also be used to estimate the size of the SDMCs. Various instruments are commercially available for the sizing and counting of cells or other particles. The Coulter particle analyzers available from Coulter Electronics, Hialeah, Florida have been found useful in this regard.
20 Specifically the Coulter NM4AM multi-angle submicron particle analyzer has been successfully employed. Vehicle size may also be estimated using standard column chromatography techniques. The SDMCs have also been
25 analyzed by testing the efficacy of the SDMC preparation over standard commercial preparations of the passenger molecule. The SDMCs have been found to have successfully encapsulated the molecule of interest by utilizing standard tests for the efficacy of the
30 passenger molecule. For example, pesticides may be tested for efficacy in killing insects and antibiotics for efficacy in standard microbiological assays.

It has been found that SDMCs exhibit substantial size homogeneity. The size is believed to be dependent

on the passenger molecule and identity of the amphipathic materials utilized, but it has been demonstrated that within one preparation of SDMCs, the size range is very compact. This characteristic is believed to be important in several applications of SDMCs including in vivo drug delivery.

The SDMCs have also been tested to be stable to heat sterilization and cobalt irradiation sterilization, which widens their utility for uses where sterility is required.

The optically clear solution is shelf-stable for months which allows one to delay SDMC formation until a later date. The organization step may be performed by the end user in many applications such as pesticide application by aerosolization, among others.

A sustained-release wound dressing is disclosed which utilized SDMCs in a foam bandage material. The foam bandage material suitable for the invention is preferably a crosslinked foam consisting of a mixture of polyolefins and other polymers (usually aryl-containing polymers) to form a three-dimensional network. Examples of commercially available forms of this material are Hypol® FMP 2002, marketed by W.R. Grace & Company (Lexington, Mass. 02173), and the Kontour sterile sponge, marketed by Winfield Laboratories, Inc. (P.O. Box 832616, Richardson, Texas 75081). Other foam bandage material may be used as long as it is capable of loading the SDMCs and nontoxic to animals at the wound site and are preferably hydrophilic, although they may be hydrophobic.

A method of wound treatment utilizing the sustained-release wound dressing is suitable for treating wounds that require at least about 30 minutes of therapy up to about seven days. The medicament is

released slowly over the treatment time. A non-adherent dressing material may be applied to the wound prior to the foam bandage material.

5 The non-adherent dressing should be made from biocompatible synthetic or naturally occurring fibers arranged in a matrix having pores of a size large enough to allow the SDMCs to pass from the foam dressing to the wound site. Such wound dressings are available commercially from several companies. An example of this
10 type of dressing is N-Terface® interpositional surfacing material which is available from Winfield Laboratories, Inc. in Richardson, Texas 75083.

The following examples are intended to illustrate the invention, but is to be understood that various
15 modifications thereof will be apparent to one skilled in the art and it is intended to cover such modifications as fall within the scope of the appended claims and that the examples are submitted for the purpose of providing a better understanding of the present invention and are
20 not to be construed as limiting the scope thereof.

Example 1: SDMCs Containing Gentamicin

A sample of 200 mg of soy lecithin was solubilized at room temperature with 20 mg of gentamicin base in 5 ml of absolute ethanol. Two ml of water was added to
25 the solution which resulted in a turbid suspension. Six ml of absolute ethanol was added to the suspension yielding an optically clear solution. SDMCs were formed by dilution of 1 ml of final solution into 10 ml of aqueous solution. The resulting opalescent suspension
30 of SDMCs was characterized by chromatographic separation over a Sepharose CL 4B column. The SDMCs were found to entrap virtually 100% of the starting gentamicin base as determined by a generally accepted bioassay of SDMCs

containing gentamicin base to inhibit the growth of E. coli.

Example 2: SDMCs Containing Vitamin A

5 A sample of 100 mg of soy lecithin was solubilized at room temperature with 10 mg of retinol (vitamin A) in 2.5 ml of absolute ethanol. One ml of water was added to the solution which resulted in a turbid (cloudy) suspension. Three ml of absolute ethanol was added to the suspension yielding an optically clear solution.
10 SDMCs were formed by dilution of 1 ml of final solution into 10 ml of aqueous solution.

Example 3: SDMCs Containing Vitamin E

The procedure in Example 2 was followed except that vitamin A was replaced with vitamin E (α -tocopherol).

15 Example 4: SDMCs Containing Vitamin D2

The procedure in Example 2 was followed except that vitamin A was replaced with vitamin D2 (ergocalciferol).

Example 5: SDMCs Containing Vitamin D3

20 The procedure in Example 2 was followed except that vitamin A was replaced with vitamin D3 (cholecalciferol).

Example 6: SDMCs Containing Vitamin K

25 The procedure in Example 2 was followed except that vitamin A was replaced with vitamin K (2-methyl-3 phytyl-1,4-naphthoquinone, 3 phytylmenadione).

Example 7: SDMCs Containing Sterols

The procedure in Example 2 was followed except that vitamin A was replaced with sterol (cholesterol).

Example 8: SDMCs Containing Pesticides

30 A sample of 1 g of soy lecithin was solubilized into a 300 ml solution (petroleum distillate) containing 0.2% w/v mixed pyrethrins and 2.0% w/v piperonyl butoxide. Twenty ml of water was added to the solution which resulted in a turbid (cloudy) suspension. To the

suspension was added 300 ml of petroleum distillates which resulted in an optically clear solution. SDMCs were formed by aerosolization of solution into air using a trigger pump and by dilution of 1 ml of solution into 10 ml of water. The efficacy of these preparations was demonstrated by their ability to kill fleas, ants, and paper wasps when SDMCs were aerosolized using a trigger sprayer or when the solution was directly applied onto the insects.

Example 9: SDMCs as Animal Dips

The procedure in Example 8 was followed except that piperonyl butoxide and pyrethrins were replaced with malathion. The resulting solution upon dilution (200 ml into 70 liters of water) resulted in a turbid solution which was used as a flea dip for dogs.

Example 10: SDMCs as Plant Insecticide Sprays

The procedure in Example 8 was followed except that the starting concentration of piperonyl butoxide was 0.2% w/v and mixed pyrethrins 0.02% w/v. The resulting solution was proven to be insecticidal and did not injure plant leaves upon aerosolization to form SDMCs.

Example 11: SDMCs Containing Peppermint Oil

A sample of 200 mg of soy lecithin was solubilized in 5 ml of peppermint oil (1% w/v solution) in absolute ethanol. One-half ml of water was added to solution which became turbid. The turbid suspension was solubilized by addition of 5 ml of absolute ethanol. Upon dilution 1:10 to water, an opalescent suspension of SDMCs resulted. The entrapment of peppermint oil was demonstrated by a taste test evaluation comparing the SDMCs to peppermint oil in solvent alone. The evaluation demonstrated a prolonged peppermint taste resulted from the use of SDMCs as compared to peppermint oil in solvent alone.

Example 12: SDMCs Containing Vanilla

The procedure in Example 11 was followed except that peppermint oil was replaced by vanilla.

Example 13: SDMCs Containing Pineapple Oil

5 The procedure in Example 11 was followed except that peppermint oil was replaced by pineapple oil.

Example 14: SDMCs Containing Anise Oil

The procedure in Example 11 was followed except that peppermint oil was replaced by anise oil.

10 Example 15: SDMCs Containing Orange Extract

The procedure in Example 11 was followed except that peppermint oil was replaced by orange extract.

Example 16: SDMCs Containing Facial Cleansers

15 A sample of 200 mg of soy lecithin was solubilized with 10% w/v salicylic acid in 10 ml isopropyl alcohol. One ml of water was added to form a cloudy turbid suspension. Ten ml of isopropyl alcohol was added to the suspension which resulted in an optically clear solution. The solution (1 ml) was diluted into 10 ml of
20 water resulting an opalescent suspension of SDMCs. The material was tested and found to demonstrate good contact time on skin surfaces.

Example 17: SDMCs Containing Fragrances

25 Ten ml of alcohol-based perfume was solubilized with 200 mg of soy lecithin. One ml of water was added to solution resulting in a cloudy suspension. The suspension was solubilized by addition of 10 ml of absolute ethanol. SDMCs were formed by aerosolization using a trigger pump and by dilution 1:10 w/v in water.
30 The SDMCs were tested by application to skin. It was found that fragrances could be detected by olfaction longer than standard preparations were so detectable.

Example 18: SDMCs in Mouthwash

A sample of 300 mg of soy lecithin was solubilized in 30 ml of 70% w/v alcohol 38B containing 1.0% of oil of peppermint w/v. Three ml of water was added to the solution which resulted in a cloudy suspension. Thirty ml of 70% v/v alcohol 38B was added to suspension to form a solution. The mouthwash was tested by dilution in saliva upon gargling and by prior dilution 1:10 v/v of solution into water prior to gargling. The results demonstrated prolonged contact of SDMCs in mouth by taste of peppermint oil SDMCs when compared with mouthwash lacking SDMCs.

Example 19: SDMCs as Hair Spray

To a 20 ml sample of a commercially available liquid hair spray was added 200 mg of soy lecithin. To the solution was added 2 ml of water resulting in a cloudy suspension. Twenty ml of commercially available liquid hair spray was added to suspension resulting in an optically clear solution. The solution was aerosolized using a finger pump and found effective as a hair spray.

Example 20: Stability of SDMC Forming Solution

An optically clear solution formed as describe in Example 8 was stored at room temperature for 15 months and demonstrated an optically clear solution which, upon aerosolization or dilution into water resulted in an opalescent SDMC suspension which was active as an insecticide in killing ants, fleas, and paper wasps.

Example 21: SDMCs in A Gauze Pad Dressing

The procedure in Example 1 was followed resulting in a clear solution which, upon dilution, formed an opalescent suspension of SDMCs entrapping gentamicin base. The suspension was aerosolized onto gauze pads. SDMCs formed on the surface and were allowed to dry.

After drying, the bandage material was tested in bioassays using generally accepted laboratory procedures and it was found that there was active gentamicin base. The bandage material onto which SDMCs were aerosolized was saturated with water and allowed to stand. The water was removed and yielded an opalescent suspension of SDMCs which contained active gentamicin base when tested by bioassay with E. coli.

Example 22: Antimicrobial SDMCs in Tampons

The procedure would be the same as employed in Example 21, except that tampons would be used rather than gauze pads.

Example 23: Entrapment of PCMX (Poly-Chloro-Meta-Xylenol)

To 185 ml of ethanol was added 18.5 ml of water. 295 ml. of Tween detergent was added to ethanol/water mixture. 50 ml soy lecithin was added to the above solution. 165 grams of PCMX was added and stirred to form a yellow clear solution. The clear yellow PCMX solution was diluted 1:10 in water. This dilution yielded an optically turbid solution of solvent dilution microcarriers containing solubilized PCMX.

Example 24: Antimicrobial Mouthwash

To 200 ml of a 70% ethanol-containing commercial mouthwash base was added a solution containing 45 ml of ethanol, 20 grams of soy lecithin, 0.5 grams of PCMX and 5 ml of water. The solutions were mixed and yielded a final solution containing 0.2% PCMX. The antimicrobial activity of the resulting mouthwash was tested and found to be increased over both commercial mouthwash and mouthwash lacking SDMCs but containing PCMX.

Example 25: Intravenous Admixture for Tetrachlordecaoxid

An intravenous solution for injection (i.v. admixture) was prepared. Into 50 ml of ethanol was solubilized 6.9×10^8 I.U. of Tetrachlordecaoxid (TCDO) and 5 grams of soy lecithin. Water (5 ml) was added to the ethanol solution to form a turbid solution. 50 ml of ethanol was added to clarify the turbid solution. SDMCs were prepared by dripping TCDO solution into 1 liter of 0.9% w/v saline. The SDMCs which resulted by dispersion into saline were analyzed by using light scattering to detect the presence of the vesicles. A Coulter NM4AM multi-angle submicron particle analyzer (Coulter Electronics, Hialeah, Florida) was utilized according to the manufacturer's instructions for the light scattering technique. Antimicrobial activity was accessed and found to be present at least 4 days after dilution using generally accepted laboratory techniques with E. coli.

Example 26: Gentamicin In An i.v. Admixture

An i.v. admixture of gentamicin was prepared as described in Example 25 by substituting 0.1 grams gentamicin for TCDO.

Example 27: Gentamicin SDMC's in Foam Wound Dressing

To a solution of 50 ml of methylene chloride was added 10 grams of soy lecithin, 0.1 grams of gentamicin base and 5 ml of water. 50 ml of additional methylene chloride was added. Onto a commercial surgical foam wound bandage was poured the above solution and the methylene chloride allowed to evaporate. The sponge material containing the SDMC forming solution was mixed with water and evaluated using light scatter as described in Example 25. The size of SDMC's which

emerged from foam material was from about 190 to 200 nm (mean size 180). The foam material with SDMC forming solution was tested in bioassays using E. coli and it was found that there was active gentamicin base as determined by standard antimicrobial test procedures.

Example 28: Silver Sulfadiazene SDMC's in Foam Wound Dressing

The procedure as in Example 27 was repeated with the exception that silver sulfadiazene (1% w/w) was added in place of gentamicin base. The mean particle size was found to be about 210 nm.

Example 29: TCDO in a Foam Wound Dressing

6.9×10^7 I.U. TCDO was impregnated into foam wound dressing as described for gentamicin in Example 27. The mean size was found to be 220 nm.

Example 30: SDMC containing Methoprene in Foam Wound Dressing

The procedures in Example 27 was repeated with exception that methoprene (0.2% w/w) replaced gentamicin.

Example 31: Fibronectin in Foam Wound Dressing

10 grams soy lecithin and 50 mg of fibronectin was impregnated into foam as in Example 27. SDMC's were consistent with the size structure of other SDMCs, having a mean size of 190 nm.

Example 32: Stability of Passenger Molecule Activity Over Time.

Antibacterial activity of the 2.5% PCMX containing SDMCs after thirty days room temperature storage and 1 hour at 70°C was testing by spotting 20 ul formed solution in the center of a lawn of E. coli strain Y1089. (The lawn was created by growing Y1089 at 30°C in Luri Broth [LB] broth until an optical density of 0.1 at 600 nm was achieved). Twenty ul of the E. coli

suspension was spotted in the center of a LB plate and spread with a sterile inoculating loop. Plates to be tested were held for 18 hours at 30°C until the antibacterial effects could be seen and measured in the confluent lawn of E. coli.

It was shown that the small amount of residual solvent and other components used to entrap (encapsulate) PCMX had no inhibitory effect on microbial growth (no zone of growth inhibition was seen).

A 3% solution of non-encapsulated PCMX was spotted in a like manner and was found to create a 8 mm zone of growth inhibition compared to SDMC. Encapsulated PCMX created a 25 mm zone. No significant reduction in the ability of encapsulated PCMX to inhibit bacterial growth was noted when procedures using 30 day old or heat treated SDMCs (30 day old SDMCs heated at 70°C for one hour) were compared.

Example 33: Comparison of PCMX SDMC Activity to a Commercial Preparation of PCMX

The antibacterial activity of SDMCs containing PCMX (2.5%) as a passenger molecule was compared against a commercial preparation of PCMX (Ultradex (Dexide Inc.) (3%)). Both solutions were diluted 1:2 v/v in LB broth using standard bacteriostatic and bacteriocidal assay techniques (1 ml total volume). After dilution of the two antimicrobial preparations, 0.1 ml of a 0.1 O.D. solution of E. coli Y1089 was added to each dilution tube. All tubes were incubated at 30°C for 18 hours. After the incubation, each dilution was tested for microbial growth by removing a small amount of broth using a sterile inoculating loop and streaking on a LB plate. After incubating the plates for 18 hours at 30° growth inhibition at each dilution was determined by examining the plates for growth of Y1089. Bacterial

growth inhibition by Ultradex (3%) stopped a dilution of 1:64 v/v. The 2.5% PCMX SCMC preparation inhibited growth up to a dilution of 1:1024. Therefore, the preparation has 16-32X better bacteriocidal activity than the Ultradex 3% solution.

Example 34:

A mouthwash was formulated employing 2.5% PCMX. Antibacterial activity of the mouthwash without PCMX was tested and no inhibition of E. coli was found using the standard plate inhibition assay, even though the mouthwash contained 70% ethanol. A 2.0% solution of PCMX in the mouthwash was prepared and upon testing found to achieve a zone of 19 mm compared to a 25 mm zone which was created by only a 0.2% solution of a SDMC encapsulated preparation.

Example 35:

A new encapsulated 5% PCMX suspension was tested using the E. coli plate inhibition assay. The control plate showed no zone of bacterial inhibition compared to the free PCMX that had a zone approximately 20 mm. The 5% free suspension did not achieve a complete inhibition of bacteria within the 20 mm zone. The SDMC preparation in contrast, showed complete inhibition of bacterial growth with a 35 mm zone due to the solubilization of the agent and even distribution over the surface.

Example 36: SDMC Size Distribution, Time and Heat Stability

The size distribution of solvent dilution microcarriers containing 2.5% PCMX was tested using a Coulter NM4AM multi-angle sub micron particle analyzer as previous described. Batch A was prepared on the same day as Batch B and as can be seen in Table I, the size of the SDMCs is fairly homogenous and stable over time and after heating at 70°C for 1 hour.

Table I

SDMC	Size (Day 1)	Size (Day 30)	Size Day 30 after Heating at 70°C for 1 hour
Batch A	130-230nm (mean 180)	105-190nm (mean 169)	100-140 hours (mean 123)
Batch B	180-300nm (mean 227)	NT	NT

NT=Not Tested

Example 37: SDMCs in a Vaginal Sponge
Contraceptive

SDMCs would be prepared as described in Example 2, except that estrogen or estrogen-like compounds would be utilized as the passenger molecule. In the alternative, a spermicidal agent such as nonoxynol-9 could be employed as the passenger molecule.

Example 38: Sustained Release of Tobramycin SDMC
From Foam Wound Dressing

To a solution of 75 ml of dichloromethane was added 10 grams of soy lecithin and 200 mg of tobramycin sulfate in 5 ml of water. The solution was mixed by shaking and 4 ml were applied onto each side of the 1" x 1" foam bandage material and allowed to air dry. Four ml of a solution comprising 20 mg of tobramycin sulfate in 8 ml of water was applied onto each side of 10 additional foam bandage material pieces (1" x 1") and allowed to air dry. The foam bandage pieces were placed onto a grid support, wetted with 5 ml of water and 2 ml of eluent was collected which flowed through the foam dressing and into the underlying receptacle. The foam dressings were wetted subsequent times and 2 ml of eluent was collected. The antimicrobial activity of

eluent was determined using standard antimicrobial inhibition assays using E. coli strain Y-1089. The results as shown in Table II.

Table II

Release of Tobramycin From Foam Dressing

Collection Point	Aqueous Tobramycin	SDMC Entrapped Tobramycin
Concentration mg per 2 ml		
1	19.0	0.50.
2	0.50	0.50
3	0.10	0.50
4	0.10	0.55
5	less than 0.10	0.45
6	N.D.*	0.45
7	N.D.	0.50
8	N.D.	0.50
9	N.D.	0.50
10	N.D.	0.45
11	N.D.	0.50
12	N.D.	0.45
13	N.D.	0.50
14	N.D.	0.45
15	N.D.	0.50
16	N.D.	0.50
17	N.D.	0.55
18	N.D.	0.50

*N.D. = Not Detected

Example 39: Sustained Release of SDMC from Foam Wound Dressing

To a solution of 75 ml of dichloromethane was added 10 grams of soy lecithin and tracer amounts of ¹⁴C - Dipalmitoylphosphatidylcholine (DPPC) and 5 ml of water. The solution was mixed by shaking and 4 ml were applied onto each side of a 1" x 1" foam bandage material and allowed to air dry. The foam bandages were placed onto a grid support, wetted with 5 ml of water and 2 ml of

eluent was collected. Eluent samples were assayed by liquid scintillation counting techniques. The results demonstrated that uniform amounts (between 1-3%) of SDMCs were collected after each application of fluid. Results indicated that over 25 applications of fluid were required to exhaust the foam bandage of SDMCs.

Example 40: Entrapment of Tobramycin in SDMC as It Elutes from Foam Wound Dressing

To a solution of 75 ml of dichloromethane was added 10 grams of soy lecithin (with tracer amounts of ^3H -phosphatidylcholine) and 200 mg of tobramycin sulfate in 5 ml of water. The solution was mixed by shaking and 4 ml were applied onto each side of 1" x 1" foam bandage material and allowed to air dry. The bandage materials were placed onto a grid support as in Example 1 and wetted with 5 ml of water. The eluents for the first nine wettings were discarded. After ten repeated wettings the eluent was collected and passed over a Sephadex G-150 column. The material which was excluded by the column and included by the column bed was assayed for tobramycin using standard antimicrobial assays with E. Coli strain Y-1089. The material which was excluded was subjected to turbidity measurements and laser light scattering analysis. The sizes of the SDMCs were consistent with those previously observed between 0.15 μm and 0.3 μm and when assayed for tobramycin demonstrated that the antibiotic was indeed entrapped within the SDMCs which eluted from the foam bandage material. The included volume contained a small amount (less than 10% of the total tobramycin) which had either not been entrapped in SDMCs or had leaked out of SDMCs during transit from foam dressing or over the Sephadex column.

Example 41: Stability of SDMC Encapsulated
Materials As They Leave Foam Bandage Material

To a solution of 50 ml of dichloromethane was added 10 grams of soy lecithin, 6.9×10^7 I.U. of tetrachlorodecaoxid ("TCDO") and 5 ml of water, 50 ml of additional dichloromethane was added and the resulting solution was mixed by shaking. Four ml of solution were applied onto each side of 1" x 1" foam bandage material and allowed to air dry. Eight ml (4 ml onto each side) of a solution containing 5.0×10^6 I.U. of TCDO was applied onto an additional 1" x 1" foam bandage material. The bandage materials were placed onto a grid support, wetted with 5 ml of water and 2 ml aliquots were collected from both the SDMC entrapped TCDO sponges and the sponges impregnated with TCDO alone. The aliquots were analyzed for antimicrobial activity immediately and stored at room temperature. At subsequent times (for 48 hours) aliquots were again assayed for TCDO activity. The results of the percentage of initial activity retained in each aliquot is shown in Table III.

Table III
Stability of SDMC Entrapped TCDO Eluent
From Foam Wound Bandage

Hours After Elution From Bandage	<u>Percentage of Initial Antimicrobial Activity</u>	
	TCDO	SDMC Entrapped TCDO
0	100	100
2	40	85
4	20	65
8	less than 1	60
24	N.D.*	55
36	N.D.	50
48	N.D.	50

*N.D. = Not Detected

Example 42: Stability of SDMC Entrapped Material
in Wet Bandage Environment

Foam bandage materials were prepared as in Example 4 (with either TCDO or SDMC entrapped TCDO). The foam bandage materials were placed onto a support grid and wet with 5 ml of water. Two ml eluent was collected at 4 hours and at 12-hour intervals for 4 days. The percentage of initial antimicrobial activity at each collection time was determined using standard antimicrobial assays. The results are shown in Table IV.

Table IV
Stability of SDMC Entrapped TCDO In
Wet Foam Wound Bandage

Hours After Wetting of Bandage	<u>Percentage of 4 Hour Antimicrobial Activity</u>	
	TCDO	SDMC Entrapped TCDO
4	100	100
12	less than 1	85
24	N.D.*	85
36	N.D.	85
48	N.D.	80
60	N.D.	80
72	N.D.	80
84	N.D.	80
96	N.D.	80

*N.D. = Not Detected

Example 43: Stability of SDMCs to Osmotic Stress

To a solution of 25 ml of dichloromethane was added 5 grams of soy lecithin and 5 ml of water. Twenty-five ml of additional dichloromethane was added and the resulting solution was mixed by shaking. Four ml of solution were applied onto each side of 1" x 1" foam bandage material and allowed to air dry. The foam

bandages were placed onto a grid support, wetted with 5 ml of water and 2 ml aliquots of eluent were collected. To aliquots of eluent containing empty SDMCs were added increasing concentrations of sucrose or water, thus placing the SDMCs under increasing osmotic stress. Changes in SDMCs were monitored using laser light scattering analysis. Results are shown in Table V.

Table V
Resistance of SDMCs to Increased Osmatic Stress

Micro Osmoles Osmatic Pressure	Percentage Sucrose	Size of SDMC NM
539	0	125 \pm 10
1,100	5	125 \pm 20
2,156	10	150 \pm 30
4,312	20	150 \pm 30
6,624	30	150 \pm 30
17,248	40	150 \pm 30

Example 44: Stability of SDMCs to Detergent Stress
SDMCs were prepared as in Example 6. To the eluent containing empty SDMCs were added either water or increasing amounts of Tween 20 (a commercial detergent). The effects or size of SDMCs was monitored using laser light scattering analysis. Results are shown in Table VI.

Table VI
Resistance of SDMCs to Increased
Detergent Concentration

5	Percentage Volxme/Volume Tween 20	Size of SDMCs (NM)
	0	190
10	0.15	190
	0.3	190
	0.75	190
	1.2	205

15 Example 45: Thermal Stability of Dry Tobramycin
SDMC Forming Foam Wound Dressings

20 To a solution of 50 ml of dichloromethane was added
10 grams of soy lecithin and 200 mg of tobramycin
sulfate in 5 ml of water. Fifty ml of additional
25 dichloromethane was added and the solution was mixed by
shaking. Eight ml of solution (4 ml per side) was added
to a 1" x 1" foam wound bandage material which was then
allowed to air dry. The materials were analyzed for
residual dichloromethane by high pressure liquid
30 chromatography and found to contain no detectable
residual dichloromethane. The 1" x 1" foam wound
materials were packaged individually in heat sealed bags
and stored at room temperature for two months. At the
end of two months the packages were opened and a
35 representative first sample of SDMC-forming foam wound
bandages were removed, placed onto grid supports, and
wetted with 5 ml of water. Two ml of eluent containing
SDMC-entrapped tobramycin were collected from the first
sample. A second representative sample of SDMC-forming
foam wound bandages were stressed by heating to +70°C
for three days. A third representative sample of SDMC-

forming foam wound bandages were stressed by freezing at -70°C for three days, then allowed to equilibrate to room temperature. These stressed foam wound dressings were then placed onto grid supports, wetted with 5 ml of water, and 2 ml of eluent containing SDMC-entrapped tobramycin was collected. All samples were subjected to analysis for tobramycin entrapped as explained in Example 3. The results are shown in Table VII.

Table VII

Effect of Thermal Stress of Tobramycin Entrapped in SDMC Forming Foam Wound Dressing

Temperature	Concentration of Tobramycin Entrapped in SDMC (mg per ml)
Room Temperature	0.5 mg/ml
+70°C	0.5 mg/ml
-70°C	0.5 mg/ml

Example 46: Thermal Stability of Dry Silver Sulfadiazine SDMC-Forming Foam Wound Dressing

To a solution of 10% weight per volume soy lecithin in ethanol (192 ml) was added 418 grams of methyl paraben and mixed by shaking. To the resulting solution was added 4.8 grams of silver sulfadiazine and mixed by shaking. One-hundred and twenty ml of Tween 20 was added to the solution which was then mixed by shaking. Dichloromethane (720 ml) was then added to the solution and mixed by shaking. Sixteen ml of this solution was placed on each side of a 4" x 4" foam wound bandage material. This was allowed to air dry. The 4" x 4" foam wound material was cut into 1" x 1" square pieces. One representative sample of 1" x 1" pieces was placed onto a grid support and wetted with 5 ml of water. Two

ml of eluent containing SDMC silver sulfadiazine was then collected. A second representative sample of the 1" x 1" pieces of foam wound material was stressed by heating to +70°C for three days. A third representative sample of the 1" x 1" piece was stressed by freezing at -85°C for three days, then allowing equilibration to room temperature. These stressed foam wound dressings were then placed onto grid and treated as above. Eluent was collected after each of the ten applications of 2 ml of water to each 1" x 1" square test piece. All samples were subjected to analysis for silver sulfadiazine antimicrobial activity using standard microbiological techniques. The results are shown in Table VIII.

Table VIII

Effect of Thermal Stress of Silver Sulfadiazine
Entrapped in SDMC Forming Wound Dressing

Temperature	Concentration of Silver Sulfadiazine Entrapped in SDMC	
	First Elution	Tenth Elution
Room Temperature	21	20
-85°C	20	21
+70°C	20	21

Example 47: Sustained-Release of SDMC Entrapped
Tobramycin from Wet Foam Wound Material Over Time

Foam wound materials containing tobramycin sulfate were prepared as shown in Example 1. Once the materials were placed onto grid supports they were maintained at room temperature and covered with a foil wrap. Every 12 hours for nine days, 5 ml of water was applied onto the foam bandage materials and eluent was collected. Two ml samples containing SDMC-entrapped tobramycin were

assayed for tobramycin antibiotic activity using standard antimicrobial assays. The results are shown in Table IX.

Table IX
Sustained Release of Tobramycin from
SDMC Forming Wound Dressing

	Time (Days)	SDMC Entrapped Tobramycin Concentration ($\mu\text{g/ml}$)
5	0	400
	0.5	410
	1.0	415
	1.5	415
10	2.0	415
	2.5	405
	3.0	405
	3.5	390
	4.0	400
15	4.5	405
	5.0	405
	5.5	410
	6.0	405
	6.5	410
20	7.0	410
	7.5	410
	8.0	415
	8.5	405
25	9.0	410
30		

Example 48: Sustained Release of SDMC Entrapped
Gentamicin From Wet Foam Wound Material Over Time

Foam wound materials containing gentamicin sulfate were prepared as shown in Example 1. Once materials were prepared they were placed onto grid supports and maintained at room temperature. All were covered with a foil wrap. Every 12 hours for nine days, 5 ml of water was applied onto the foam bandage materials and eluent was collected. Two ml samples containing SDMC entrapped

gentamicin were assayed for gentamicin antibiotic activity using standard antimicrobial assays. The results are shown in Table X.

Table X

Sustained Release of Gentamicin From Wet
SDMC Forming Wound Dressing

Time (Days)	SDMC Entrapped Gentamicin Concentration (µg/ml)
0	200
0.5	200
1.0	205
1.5	205
2.0	205
2.5	205
3.0	200
3.5	175
4.0	190
4.5	200
5.0	200
5.5	200
6.0	200
6.5	205
7.0	195
7.5	200
8.0	200
8.5	200
9.0	205

Example 49: Preparation and Sterilization of
Polymyxin B SDMCs in Foam Wound Dressing

To a solution of 125 ml of dichloromethane was added 500,000 units (10 ml in aqueous solution) of polymyxin B. The resulting solution was mixed by shaking. To the solution was added 20 ml of soy lecithin (Alcolec x-tra A) and the resulting solution was mixed by shaking. Four ml of above solution was added to each side of a 1" x 1" foam wound material

which was allowed to air dry. The materials were placed into heat sealed pouches and sterilized by use of cobalt irradiation (3.2 megarads). The resulting materials were assayed by placing them onto grid supports, wetting with 5 ml [water] and collecting 2 ml of eluent containing SDMC entrapped polymyxin B. The eluent contained fully active entrapped antibiotic after irradiation as determined by use of standard antimicrobial assay techniques.

Example 50: Preparation and Sterilization of Kanamycin SDMCs in Foam Wound Dressing

To a solution of 125 ml of dichloromethane was added 1 gram of kanamycin sulfate in 10 ml of aqueous solution. To the resulting solution was added 20 ml of soy lecithin (Alcolec S). The solution was mixed by shaking. Four ml of the solution was applied to each side of a 1" x 1" foam wound dressing, which was then allowed to dry. These materials were placed in foil heat sealed bags and subjected to sterilization by use of cobalt irradiation (3.2 megarads). The materials were assayed for antibiotic activity as described in Example 12. The eluent contained fully active entrapped antibiotic after irradiation by using standard antimicrobial assay techniques.

Example 51: Sustained Release of SDMC Entrapped Silver Sulfadiazine From Wet Foam Wound Materials Over Time

Foam wound materials were prepared as described in Example 9. Once the materials were placed onto grid supports, they were maintained at room temperature and covered with a foil wrap. Every 12 hours for seven days, 5 ml of water was applied onto the foam bandage materials and eluent was collected. Two ml samples containing SDMC entrapped silver sulfadiazine were

assayed for silver sulfadiazine antimicrobial activity using standard microbiological techniques. The results are shown in Table XI.

Table XI
Sustained Release of Silver Sulfadiazine From
Wet SDMC Forming Foam Wound Dressing

Time (Days)	SDMC Entrapped Silver Sulfadiazine Concentration ($\mu\text{g/ml}$)
0	18
0.5	20
1.0	20
1.5	19
2.0	20
2.5	20
3.0	21
3.5	20
4.0	19
4.5	20
5.0	21
5.5	20
6.0	21
6.5	20
7.0	20

Example 52: Preparation and Sterilization of
Cefoxitin Entrapped in SDMCs

To a solution of 15 ml of 10% (weight per volume) NaCl in water was added 4 grams of cefoxitin. The mixture was shaken and resulting SDMCs entrapping cefoxitin were sterilized using Cobalt irradiation (2.5 megarads). The SDMCs were assayed for cefoxitin antimicrobial activity using standard microbiological techniques and found to both entrap the cefoxitin and preserve its activity both during one week storage at 4°C and through irradiation sterilization.

Example 53: Preparation and Sterilization of Amakacin Entrapped in SDMCs

To a solution of 15 ml of 10% (weight per volume) soy lecithin (Alcolec LKE granules) was added 85 ml of 0.95% (weight per volume) NaCl in water containing 2 grams of amakacin sulfate. The mixture was shaken and resulting SDMCs entrapping amakacin were sterilized using cobalt irradiation (2.5 megarads). The SDMCs were assayed for amakacin antimicrobial activity using standard microbiological methodology and found to both entrap amakacin and preserve the activity of the antibiotic both during storage at 4°C and through irradiation sterilization.

Example 54: Preparation of Kanamycin Entrapped SDMCs

To a 40 ml solution of 0.05 potassium phosphate (pH 7.0) was added 1 gram of tobramycin sulfate. Three ml of a 10% (weight per volume) soy lecithin in ethanol solution was added to tobramycin containing solution. The resulting SDMC containing mixture was swirled to entrap tobramycin with SDMCs. To adjust volume 57 ml of 0.05 M potassium phosphate was added and resulting suspension was passed through a 0.45 µm filter into a sterile vial.

Example 55: Preparation of a Stable Cyclosporin Admixture

To 2 ml of a 10% (weight per volume) soy lecithin in ethanol solution was added 3 mg of cyclosporin. The solution was mixed by swirling. To form SDMC 50 µl aliquot of above solution was mixed with 450 µl of water. The resulting SDMCs containing cyclosporin were analyzed using laser light scattering and found to be approximately 200 µm in diameter. The admixture was stored at room temperature for one year and subjected to

testing as above. The results found no change in size (200 μ m diameter) and no precipitation of cyclosporin in the admixtures during storage for one year.

Example 56: Use of Novel Wound Dressing Package
Containing Gentamicin Sulfate for Treatment of Soft
Tissue Infections in Rats

A model of soft tissue infection was established in Sprague Dawley rats. Rats were anesthetized and a 3 x 3 cm square of skin was excised from the back exposing paraspinus muscles. One-half ml of a suspension containing 1×10^8 cfu/ml of Pseudomonas aeruginosa was injected into the superficial fascia of each paraspinus muscle for a total volume of 1 ml. Wounds were covered with a non-adherent dressing material (N-terface® interpositioned surfacing material, available from Winfield Laboratories, Richardson, Texas 75083) and either a foam wound material or a predried foam wound dressing prepared by impregnation of a SDMC forming solution consisting of 0.5 grams of soy lecithin and 2 mg gentamicin sulfate applied onto 1" x 1" foam material (prepared as described in Example 1). In all cases bandage materials were moistened with 5 ml of either sterile water for 40 rats, 5 ml of sterile water for rats receiving SDMC gentamicin (40 rats) or 5 ml of sterile water containing 330 μ g of gentamicin sulfate (40 rats). Animals were redampened every 12 hours as above for a duration of three days. During the three-day study at 24-hour intervals, groups of ten rats were sacrificed and the paraspinus muscle harvested obtaining between 1.5 and 3 grams of tissue. Colony forming units (CFU) of P. aeruginosa [per] 1 gram of muscle tissue was determined using standard microbiological techniques. The results for each treatment group are shown in Table XII.

Table XII

Treatment of Soft Tissue Infections with Gentamicin

Treatment Groups	Hours after Treatment (percent of time 0 bacteria per gram of tissue)			
	0	24	48	72
Untreated Controls	100	>100	>100	>100
Aqueous Gentamicin	100	>100	>100	>100
SDMC Gentamicin	100	45	2	<0.01

Example 57: Use of Novel Wound Dressing Package Containing Silver Sulfadiazine for Treatment of Soft Tissue Infection in the Rat

A model of soft tissue infection was established in Sprague Dawley rats as described in Example 17. All animals were treated as described in Example 17 with the following exceptions. Treatment groups consisted of 1) animal receiving foam wound dressing (wet with sterile water), 40 animals, 2) animals receiving 3 grams of 1% silver sulfadiazine (30 mg) (Silvadene® Cream) applied into the wound, scrubbed away and reapplied twice daily for three days (40 animals) and 3) animals receiving a pre-dried foam wound material impregnated with SDMC forming solution consisting of 30 mg of silver sulfadiazine and 0.5 grams of soy lecithin (prepared as described in Example 9). The results for each treatment group are shown in Table XIII.

Table XIII
Treatment of Soft Tissue Infections
With Silver Sulfadiazine

Treatment Groups	Hours after Treatment (percent of time 0 bacteria per gram of tissue)			
	0	24	48	72
Untreated Controls	100	>100	>100	>100
Silvadene Cream	100	68	40	22
SDMC Silver Sulfadiazine	100	40	12	<0.01

Example 58: Use of SDMC Entrapped Cefoxitin to Treat Fatal Bacteria Septicemia Resulting From Mixed Bacterial Peritonitis

A model for fatal septicemia resulting from mixed bacterial infections were established in Sprague Dawley rats. Rats were anesthetized and a midline incision made into abdomen. The peritoneal cavity was irritated with a barium solution and 1 gram of human fecal material was implanted into the peritoneal cavity. Animals were surgically closed. Blood samples were removed from caudal vein at zero, four hours and subsequent 24-hour intervals for the duration of a four-day study.

Infections were established in a group of 40 animals. In a group of ten animals, no treatment was initiated. In a group of ten animals, cefoxitin 1.5 mg/kg was administered i.m. at the time of surgical closure. In a group of ten animals, cefoxitin 1.5 mg/kg was administered into the peritoneal cavity at the time of surgical closure. In a group of ten animals, SDMC-entrapped cefoxitin 1.5 mg/kg was administered at the time of surgical closure. In a group of ten animals, empty SDMCs were administered i.p. at the time of

surgical closure. The results of this study are shown in Table XIV.

Table XIV
Treatment of Fatal Septicemia Resulting
From Mixed Bacterial Peritonitis

Treatment Groups	Bacteria (cfw/ml) In Blood Per Ml Hours After Treatment				
	0	4	24	48	72
Controls	0	1×10^4	1×10^7	$>1 \times 10^7$	$>1 \times 10^7$
Cefoxitin (i.m.)	0	1×10^3	1×10^4	1×10^4	1×10^4
Cefoxitin (i.p.)	0	1×10^3	1×10^4	1×10^4	1×10^4
SDMC cefoxitin (i.p.)	0	$>1 \times 10^1$	$>1 \times 10^1$	$>1 \times 10^1$	$>1 \times 10^1$
Empty SDMCs	0	1×10^3	1×10^6	1×10^6	1×10^6

Example 59: Prevention of Fatal Septicemia
Resulting From Mixed Bacterial Peritonitis By Use of
SDMC-Entrapped Cefoxitin

A model for fatal septicemia resulting from mixed bacterial infections were established in Sprague Dawley rats as described in Example 58. The mortality of each of the treatment groups is reported in Table XV.

Table XV
Mortality Due To Fatal Septicemia Results
From Mixed Bacterial Peritonitis

Treatment Groups	Mortality In Animals Following Infection	
	4 hours	72 hours
Control	0	9/10 (90%)
Cefoxitin im/ip	0	4/10 (40%)
SDMC Cefoxitin	0	0 (0%)

Example 60: Reduction of Initial Serum Blood Levels of SDMC-Entrapped Tobramycin Sulfate Following Intraperitoneal Administration

To evaluate the effect of SDMC-entrapped tobramycin on serum blood levels, SDMCs were prepared as follows: to a 40 ml solution of 0.95% saline containing 1 gram of tobramycin sulfate was added 3 ml of a 10% (weight per volume) soy lecithin (Alcolec LKE granules). The SDMC-entrapping tobramycins were formed and suspension mixed by swirling. An additional 60 ml of 0.95% saline was added and suspension swirled. Groups of five animals received either 1 ml of saline i.p., 1 ml of aqueous tobramycin sulfate (10 mg) i.p. or SDMC-entrapped tobramycin (10 mg). Animals were bled by caudal vein puncture prior to treatment and at four and twenty-four hours after treatment. Seven levels of tobramycin were determined using standard assay techniques. The results of experiments are shown in Table XVI.

Table XVI
Serum Concentrations of Tobramycin
Following I.P. Administration

Experimental Groups	Serum Concentrations (mg/ml) of Tobramycin		
	Time of Administration		
	0	4	24
Control	0	0	0
Tobramycin	0	4.5 ± 0.7	1.3 ± 0.4
SDMC Tobramycin	0	1.1 ± 0.1	1.4 ± 0.1

Example 61: Stabilization of Methoprene to
Ultraviolet Light Degradation by SDMC Encapsulation

Methoprene, 90% technical grade, was encapsulated into SDMC in the following manner. To 10 ml of a soy lecithin (Alcolec X-tra^A) was added 1 ml of Tween 20 and 1 ml of methoprene. To above mixture was added 5 ml of ethanol and swirled. To the resulting mixture 85 ml of water was added and mixed by swirling. To evaluate ultraviolet light protection by encapsulation of methoprene in SDMCs, standardized flea egg hatching studies were done on environmental surfaces (carpet, 1 ft. x 1 ft. square). Carpet samples received either no treatment, 1% methoprene applied in volatile propellant or methoprene entrapped in SDMCs as prepared above. Flea eggs were applied to the carpet samples and the percent of initial methoprene activity was determined as a function of the percentage of flea eggs which hatched. All carpet samples were exposed to ultraviolet light daily during the study period. The carpet samples were reinfected for three subsequent months. The percentage of methoprene activities for each of the experimental groups are shown in Table XVII.

Table XVII
Protection of Methoprene From Ultraviolet
Light Degradation

Experimental Groups	Percentage of Initial Pesticide Activity Time After Application Months			
	0	1	2	3
Control	0	0	0	0
Methoprene	100	0	0	0
SDMC Methoprene	100	92	89	90

Example 62: Reduction of Odor By Encapsulation of Propetamphos by SDMCs

Propetamphos was encapsulated into SDMCs in the following manner. To a 10 ml of a soy lecithin (10% weight per volume in ethanol) was added 1 ml of Tween 20 and 1 ml of propetamphos. To the above mixture was added 90 ml of water and mixed by swirling. A noticeable reduction in offensive odor was observed when compared to equal amounts of propetamphos in ethanol above.

Example 63: SDMC Containing Retinoic Acid

A sample of 100 mg of soy lecithin was solubilized at room temperature with 30 mg of retinoic acid in ethanol. One ml of water was added to the solution which resulted in a turbid (cloudy) suspension. Three ml of absolute ethanol was added to the suspension to yield an optically clear solution. SDMCs were formed by dilution of 1 ml of final solution into 10 ml of aqueous solution.

I CLAIM:

1. A method for making a solvent dilution micro-carrier vehicle comprising the steps of:

(a) mixing a bilayer-forming material with a passenger molecule in an appropriate solvent;

5 (b) adding a quantity of water to form a turbid suspension;

(c) adding a quantity of solvent to form an optically clear solution; and

10 (d) organizing said optically clear solution to form solvent dilution microcarrier vehicles.

2. The method of Claim 1, wherein said quantity of water is from about 4:1 (solvent to water) to about 10:1 (solvent to water).

3. The method of Claim 1 wherein said quantity of additional solvent is from about 15:1 (solvent to water) to about 100:1 (solvent to water).

4. The method of Claim 1 wherein said organizing comprises aerosolization of said optically clear solution.

5. The method of Claim 1 wherein said organizing comprises dilution of said optically clear solution into an aqueous solution.

6. The method of Claim 1 wherein said organizing comprises drying of said optically clear solution followed by rehydration.

7. The method of Claim 1 wherein said passenger molecule is selected from the group consisting of antimicrobials, anti-inflammatories, anti-parasitics, dyes, radio labels, radio-opaque compounds, fluorescent compounds, immunomodulating compounds, peptides, proteins, glycoproteins, lipoproteins, hormones, neurotransmitters, tumorocidal agents, growth factors, toxins, analgesics, anesthetics, monosaccharides, polysaccharides, narcotics, catalysts and enzymes.

8. The method of Claim 1 wherein said passenger molecule is lipid-soluble.

9. The method of Claim 5 wherein said optically clear solution is diluted at a ratio of from about 1 to 5 to about 1 to 100 optically clear solution to aqueous solution.

10. The method of Claim 9 wherein said optically clear solution is diluted from about 1 to 10.

11. The method of Claim 1 wherein said bilayer-forming material comprises at least one phospholipid.

12. A solvent dilution microcarrier vehicle formed by the process comprising the steps of:

- (a) mixing a bilayer-forming material with a passenger molecule in an appropriate solvent;
- 5 (b) adding a quantity of water to form a turbid suspension;
- (c) adding a quantity of additional solvent to form an optically clear solution; and
- 10 (d) organizing said optically clear solution to form solvent dilution microcarrier vehicles.

13. The solvent dilution microcarrier vehicle of Claim 12, wherein said quantity of water is from about 4:1 (solvent to water) to about 10:1 (solvent to water).

14. The solvent dilution microcarrier vehicle of Claim 12, wherein said quantity of additional solvent is from about 15:1 (solvent to water) to about 100:1 (solvent to water).

15. The solvent dilution microcarrier vehicle of Claim 12 wherein said organizing comprises aerosolization of said optically clear solution.

16. The solvent dilution microcarrier vehicle of Claim 12 wherein said organizing comprises dilution of said optically clear solution into an aqueous solution.

17. The solvent dilution microcarrier vehicle of Claim 12 wherein said organizing comprises drying of said optically clear solution followed by rehydration.

18. The solvent dilution microcarrier vehicle of Claim 12 wherein said passenger molecule is selected from the group consisting of antimicrobials, anti-inflammatory, anti-parasitics, dyes, radio labels, radio-opaque compounds, fluorescent compounds, immunomodulating compounds, peptides, proteins, glycoproteins, lipoproteins, hormones, neurotransmitters, tumorocidal agents, growth factors, toxins, analgesics, anesthetics, monosaccharides, polysaccharides, narcotics, catalysts and enzymes.

19. The solvent dilution microcarrier vehicle of Claim 12 wherein said passenger molecule is lipophilic.

20. The solvent dilution microcarrier vehicle of Claim 16 wherein said optically clear solution is diluted from about 1 to 5 to about 1 to 100.

21. The solvent dilution microcarrier vehicle of Claim 20 wherein said optically clear solution is diluted from about 1 to 10.

22. The solvent dilution microcarrier vehicle of Claim 12 wherein said bilayer-forming material comprises at least one phospholipid.

23. The solvent dilution microcarrier vehicle formed by the process of Claim 12, further characterized as being stable to heat sterilization.

24. A plurality of solvent dilution microcarrier vehicles formed by the process of Claim 12, further characterized as being generally homogeneous in size.

25. A plurality of solvent dilution microcarrier vehicles according to Claim 24, further characterized as being of a size from about 100 nm to about 800 nm.

26. The solvent dilution microcarrier vehicles according to Claim 12, wherein said passenger molecule comprises a lipid-soluble vitamin.

27. The solvent dilution microcarrier vehicle according to Claim 12 wherein said passenger molecule comprises a sterol.

28. The solvent dilution microcarrier vehicle according to Claim 12 wherein said passenger molecule comprises a pesticide.

29. The solvent dilution microcarrier vehicle according to Claim 12 wherein said passenger molecule comprises a flavoring extract.

30. The solvent dilution microcarrier vehicle according to Claim 12 wherein said passenger molecule comprises salicylic acid.

31. The solvent dilution microcarrier vehicle according to Claim 12 wherein said passenger molecule comprises a fragrance.

32. The solvent dilution microcarrier vehicle according to Claim 12 wherein said passenger molecules comprises a cosmetic ingredient.

33. The solvent dilution microcarrier vehicle according to Claim 12 wherein said passenger molecules comprises a medicament.

34. The solvent dilution microcarrier vehicle according to Claim 12 wherein said passenger molecules comprises a material for administration to a patient in an i.v. admixture.

35. The solvent dilution microcarrier vehicle according to Claim 12 wherein said passenger molecules comprises gentamicin.

36. A method for making a solvent dilution microcarrier vehicle comprising the steps of:

(a) mixing a bilayer-forming material with a passenger molecule in an appropriate solvent;

5 (b) adding a quantity of water to form a turbid suspension;

(c) adding a quantity of additional solvent to form an optically clear solution;

10 (d) applying said optically clear solution to a surface and allowing it to dry; and

(e) rehydrating said surface to form solvent dilution microcarrier vehicles.

37. An adsorbent material impregnated with an optically clear solution formed by the method comprising steps of:

5 (a) mixing a bilayer-forming material with a passenger molecule in an appropriate solvent;

(b) adding a quantity of water to form a turbid suspension;

(c) adding a quantity of additional solvent to form an optically clear solution;

10 (d) applying said optically clear solution to said adsorbent material; and

(e) allowing said optically clear solution to dry in said material.

38. The material of claim 37, wherein said adsorbent material is gauze.

39. The material of Claim 37, wherein said adsorbent material is foam.

40. The material of Claim 37, wherein said adsorbent material is a tampon.

41. A method for making a solvent dilution microcarrier vehicle comprising the steps of:

(a) mixing a bilayer-forming material with a passenger molecule in an appropriate solvent;

5 (b) adding a quantity of water to form a turbid suspension;

(c) adding a quantity of additional solvent to form an optically clear solution;

10 (d) diluting an aliquot of said optically clear solution in an aqueous solution in a ratio from about 1:5 to about 1:100 to form solvent dilution microcarrier vehicles.

42. The method according to Claim 41 wherein said optically clear solution is diluted in a ratio of from about 1 to about 10.

43. The method according to Claim 41 wherein said aqueous solution is water.

44. The method according to Claim 41 wherein said aqueous solution is saline at a concentration of about 0.9 w/v.

45. A method for forming a solvent dilution microcarrier vehicle comprising the steps of:

(a) mixing a bilayer-forming material with a passenger molecule in an appropriate solvent;

5 (b) adding a quantity of water to form a turbid suspension;

(c) adding a quantity of an additional solvent to form an optically clear solution; and

10 (d) aerosolizing said optically clear solution by mixing with air to form solvent dilution microcarrier vehicles.

46. A method according to claim 45 wherein said optically clear solution is mixed with air by spraying through a conventional sprayer.

47. An optically clear solution formed by the process comprising the steps of:

(a) mixing a bilayer-forming material with a passenger molecule in an appropriate solvent;

5 (b) adding a quantity of water to form a turbid suspension; and

(c) adding a quantity of additional solvent to form an optically clear solution.

48. The optically clear solution of Claim 47, further characterized as being stable to sterilization by heat.

49. The optically clear solution of Claim 47, further characterized as being stable to degradation for at least 30 days.

50. A sustained-release wound dressing made by the method comprising the steps of:

(a) mixing a bilayer-forming material in an appropriate solvent with a passenger molecule in aqueous solution to form a mixture;

(b) allowing said mixture to permeate into a foam bandage material to form a permeated foam bandage; and

(c) drying said permeated foam bandage.

51. The sustained-release dressing of Claim 50, wherein said bilayer-forming material comprises at least one phospholipid.

52. The sustained-release dressing of Claim 50, wherein the ratio of said appropriate solvent to said bilayer-forming material is from about 5.0 to about 7.5 ml per gram of bilayer-forming material.

53. The sustained-release dressing of Claim 50, wherein said passenger molecule is tobramycin.

54. The sustained-release dressing of Claim 50, wherein said passenger molecule is tetrachlordecaoxid.

55. The sustained-release dressing of Claim 50, wherein said passenger molecule is silver sulfadiazine.

56. The sustained-release dressing of Claim 50, wherein said passenger molecule is polymyxin B.

57. The sustained-release dressing of Claim 50, wherein said passenger molecule is kanamycin sulfate.

58. A sustained-release wound dressing made by the method comprising the steps of:

5. (a) mixing a phospholipid material dissolved in an appropriate solvent in a ratio of 1 gram phospholipid to between about 5.0 to 7.5 ml solvent, with a passenger molecule in aqueous solution to form a mixture;
- (b) applying said mixture to a foam bandage to form a permeated foam bandage; and
- (c) drying said permeated foam bandage.

59. The sustained-release dressing of Claim 58, wherein said appropriate solvent is dichloromethane.

60. The sustained-release dressing of Claim 58 wherein said phospholipid is phosphatidyl choline.

61. A sustained-release wound dressing made by the process comprising the steps of:

5 (a) mixing from about 5.0 to about 7.5 ml of dichloromethane per gram of soy lecithin with an aqueous solution comprised of a passenger molecule dissolved in about 5.0 ml of water to form SDMCs;

(b) allowing said SDMCs to permeate a foam dressing material to form a permeated foam dressing material; and

10 (c) drying said permeated foam dressing material.

62. The sustained-release dressing of Claim 61, wherein 4 ml of SDMCs are applied per cubic inch of foam dressing material.

63. The sustained-release dressing of Claim 61, wherein passenger molecule is tobramycin sulfate.

64. The sustained-release dressing of Claim 61, wherein passenger molecule is 200 mg tobramycin sulfate.

65. The sustained-release dressing of Claim 61, wherein passenger molecule is TCDO.

66. The sustained-release dressing of Claim 61, wherein passenger molecule is 6.9×10^7 I.U. TCDO.

67. A sustained-release wound dressing made by mixing an amount of methyl paraben dissolved in 10% weight per volume solution of soy lecithin in ethanol with silver sulfadiazine, a surfactant, and dichloromethane.

68. The sustained-release wound dressing of Claim 67, wherein 1 ml of 10% weight per volume soy lecithin in ethanol per 2 grams methyl paraben is mixed with from about 4.5 to about 5 grams silver sulfadiazine, about .6 ml Tween 20, and about 3.5 to about 4 ml dichloromethane.

69. A sustained-release wound dressing comprised of:

(a) a foam material; and

5 (b) 125 ml dichloromethane to about 500,000 I.U. polymyxin B in 10 ml water, 20 ml of a mixture comprising 75 to 97% soy phosphatides and 3 to 25% soy oils permeated into said foam material.

70. A sustained-release wound dressing comprised of:

(a) a foam material; and

5 (b) 125 ml dichloromethane to about 1 gram
kanamycin sulfate in 10 ml water, 20 ml of a mixture
comprising 75 to 97% soy phosphatides and 3 to 25% soy
oils permeated into said foam material.

71. A method for treating wounds, comprising the steps of:

(a) applying a sustained-release wound dressing to a wound site;

5 (b) moistening said sustained-release wound dressing with an appropriate amount of sterile water to thoroughly dampen said dressing; and

(c) allowing said dressing to stay in contact with said wound for an appropriate period of time.

72. The method of Claim 71, wherein said time is from about 30 minutes to about 7 days.

73. The method of Claim 71, further comprising applying a non-adherent dressing material to said wound site prior to applying said sustained-release wound dressing.

74. A stable cyclosporin preparation made according to the method comprising the steps of:

(a) mixing a phosphatide in an appropriate alcohol solvent with a quantity of cyclosporin to form a first solution; and

(b) adding about one part of said first solution to about nine parts of water to form said stable cyclosporin preparation comprised of solvent dilution microcarriers containing cyclosporin.

75. The preparation of Claim 74 wherein said first solution comprises about 2 ml of a 10% weight per volume soy lecithin preparation in ethanol per 3 mg of cyclosporin.

76. A solvent dilution microcarrier formed by the steps of:

(a) solubilizing about 100 mg of soy lecithin per about 30 mg of retinoic acid in ethanol;

5 (b) adding an appropriate amount of water to result in a cloudy suspension;

(c) adding an appropriate amount of absolute ethanol to result in an optically clear solution; and

10 (d) adding one volume of said optically clear solution to 10 ml of aqueous solution.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 85/02454

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC INT CL(4): A61K 9/52; B01J 13/02; A61L 15/03 US CL: 424/431,443,450; 428/402.2; 436/829; 514/155; 536/13.6,13.7		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
US	424/431,443-447,450; 436/829; 428/402.2; 514/155; 536/13.6,13.7; 264/4.3,4.6	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched *		
III. DOCUMENTS CONSIDERED TO BE RELEVANT *		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	US, A, 4,588,578 (FOUNTAIN ET AL) 13 MAY 1986 (Abstract, col. 3-9)	1-42,44-76
Y	US, A, 4,610,868 (FOUNTAIN ET AL) 09 SEPTEMBER 1986 (col. 6 & 10)	1-42,44-76
Y	US, A, 4,508,703 (REDZINIAK ET AL) 02 APRIL 1985 (Abstract, col.1 & 4, & example 12)	1-42,44-76
Y	US, A, 4,522,803 (LENK ET AL) 11 JUNE 1985 (col. 6, 7, & 18)	1-42,44-76
E	US, A, 4,839,175 (GUO ET AL) 13 JUNE 1989 (col. 14-18)	1-42,44-76
A	WO, A, 85/00515 (THE LIPOSOME COMPANY) 14 FEBRUARY 1985 (entire document)	1-42,44-76
P	WO, A, 88/04573 (THE LIPOSOME COMPANY) 30 JUNE 1988 (entire document)	1-42,44-76
P	US, A, 4,752,572 (SUNBERG ET AL) 21 JUNE 1988 (col. 6-7)	1-42,44-76
A	US, A, 4,731,210 (WEDER ET AL) 15 MARCH 1988 (entire document)	1-42,44-76
<p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
01 SEPTEMBER 1989	19 SEP 1989	
International Searching Authority	Signature of Authorized Officer	
ISA/US	DANIEL METZMAIER <i>Daniel Metzmaier</i>	

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

A	US, A, 4,649,047 (KASWAN) 10 MARCH 1987 (Abstract, col. 6, & claim 10)	74-75
A	US, A, 4,582,717 (VON BITTERA ET AL) 15 APRIL 1986	37-40, 50-70
A	US, A, 4,556,554 (CALVO) 03 DECEMBER 1985 (Abstract, col. 4, & claim 4)	37-40, 50-70
A	US, A, 4,599,226 (FOX, JR. ET AL) 01 MAY 1984 (entire document)	55, 67, 68, 71-73

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claim numbers 43, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ¹², specifically:

Claim 43 does not meet the requirements of PCT Article 6 that, 'Claims shall be clear and concise.' An aqueous solution of the independent claim 41 cannot be water by definition.

3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Searching Authority found multiple inventions in this international application as follows:

Please see Form PCT/ISA/206 of record.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.